Alto Neuroscience (Alto Neuroscience) Cash-to-Debt : 8.27 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alto Neuroscience's cash to debt ratio for the quarter that ended in Dec. 2023 was 8.27.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Alto Neuroscience could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Alto Neuroscience's Cash-to-Debt or its related term are showing as below:

ANRO' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.96 Med: 8.27 Max: No Debt
Current: 8.27

During the past 3 years, Alto Neuroscience's highest Cash to Debt Ratio was No Debt. The lowest was 4.96. And the median was 8.27.

ANRO's Cash-to-Debt is ranked better than
52.83% of 1539 companies
in the Biotechnology industry
Industry Median: 6.51 vs ANRO: 8.27

Alto Neuroscience Cash-to-Debt Historical Data

The historical data trend for Alto Neuroscience's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alto Neuroscience Cash-to-Debt Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

4.96

8.27

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Cash-to-Debt	No Debt	N/A	4.96	5.15	8.27

Competitive Comparison of Alto Neuroscience's Cash-to-Debt

For the Biotechnology subindustry, Alto Neuroscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Cash-to-Debt falls into.

Alto Neuroscience Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Alto Neuroscience's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	82.548	/	(0.125	+	9.861)
	=	8.27

Alto Neuroscience's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	82.548	/	(0.125	+	9.861)
	=	8.27

Alto Neuroscience (NYSE:ANRO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Alto Neuroscience Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024